A Phase II Study of CPI-0610, a Bromodomain and Extraterminal Protein Inhibitor (BETi) Alone or with Ruxolitinib (RUX), in Patients with Myelofibrosis (MF).

This phase 2 study analyzed bromodomain and extraterminal protein inhibitor CPI-0610 as monotherapy and in combination with ruxolitinib among patients with myelofibrosis, with the primary endpoints of evaluating the effect of CPI-0610 on transfusion dependence and spleen volume.

Journal of Clinical Oncology (ASCO 2019 Abstract)